CD8A and neoplasm: Advanced cutaneous manifestations, including tumoral lesions or erythroderma, along with significant lymph node involvement, LCT, or a shift in immunophenotype from CD4 + to CD8+, are indicative of an increased risk of progression to extracutaneous involvement.